Skip navigation
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/4026
Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_HyperlipidemiaRelatedUseHIV.pdf363,39 kBAdobe PDFVisualizar/Abrir
Título: Hyperlipidemia related to the use of HIV-protease inhibitors : natural history and results of treatment with fenofibrate
Autor(es): Caramelli, Bruno
Bernoche, Claudia Y.S.M. de
Sartori, Ana M.C
Spósito, Andrei Carvalho
Santos, Raul D.
Monachini, Maristela C.
Strabelli, Tania
Uip, Davi
Assunto: Colesterol
Lipídios
HIV - infecção
Triglicerídios
Data de publicação: Dez-2001
Referência: CARAMELLI, Bruno. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Brazilian Journal of Infectious Diseases, Salvador, v. 5, n. 6, p. 332-338, dec. 2001. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000600007&Ing=en&nrm=iso>. Acesso em 15 mar. 2010.
Resumo: Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-cholesterol, triglycerides (TG), and CD4+ T-cell counts were measured in 30 HAART-naive patients (Group I) before and after PI introduction. In a second phase of the study, the effects of fenofibrate on lipids, CPK, CD4+, and viral load were determined in 13 patients (Group II) with elevated TC or TG. In Group I, 60% of the patients showed TC or TG elevations. Average increments of 31% and 146% in TC and TG respectively (p<0.0006 and p<0.0001) were observed. In Group II, fenofibrate treatment was associated with decrements of 6.6% (TC) and 45.7% (TG) (p=0.07 and 0.0002) and no modifications on CPK, CD4+, and viral load. In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment.
Unidade Acadêmica: Faculdade de Medicina (FMD)
Informações adicionais: 7 f.
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro completo do item Visualizar estatísticas



Este item está licenciada sob uma Licença Creative Commons Creative Commons